Studie - Uterine Leiomyoma (Uterine Fibroids) – Pipeline Review, H1 2012

Uterine Leiomyoma (Uterine Fibroids) — Pipeline Review, H1 2012


Summary


Global Markets Direct’s, 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2012', provides an overview of the Uterine Leiomyoma (Uterine Fibroids) therapeutic pipeline. This report provides information on the therapeutic development for Uterine Leiomyoma (Uterine Fibroids), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Leiomyoma (Uterine Fibroids). 'Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- A snapshot of the global therapeutic scenario for Uterine Leiomyoma (Uterine Fibroids).
- A review of the Uterine Leiomyoma (Uterine Fibroids) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Uterine Leiomyoma (Uterine Fibroids) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.


Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) pipeline depth and focus of Uterine Leiomyoma (Uterine Fibroids) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 3

Introduction 4

Global Markets Direct Report Coverage 4

Uterine Leiomyoma (Uterine Fibroids) Overview 5

Therapeutics Development 6

An Overview of Pipeline Products for Uterine Leiomyoma (Uterine Fibroids) 6

Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Development by Companies 8

Uterine Leiomyoma (Uterine Fibroids) Therapeutics under Investigation by Universities/Institutes 9

Late Stage Products 10

Comparative Analysis 10

Mid Clinical Stage Products 11

Comparative Analysis 11

Uterine Leiomyoma (Uterine Fibroids) Therapeutics — Products under Development by Companies 12

Uterine Leiomyoma (Uterine Fibroids) Therapeutics — Products under Investigation by Universities/Institutes 13

Companies Involved in Uterine Leiomyoma (Uterine Fibroids) Therapeutics Development 14

Abbott Laboratories 14

Uterine Leiomyoma (Uterine Fibroids) — Therapeutics Assessment 15

Assessment by Monotherapy Products 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Drug Profiles 20

Elagolix - Drug Profile 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

Mifepristone - Drug Profile 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Uterine Leiomyoma (Uterine Fibroids) Therapeutics — Drug Profile Updates 22

Uterine Leiomyoma (Uterine Fibroids) — Product Development Milestones 24

Featured News & Press Releases 24

Aug 29, 2011: Takeda Initiates Phase II Clinical Trials Of TAK-385 In Japan 24

Jun 23, 2011: Repros Enrolls Fourth Cohort In Low Dose Proellex Study 24

Appendix 25

Methodology 25

Coverage 25

Secondary Research 25

Primary Research 25

Expert Panel Validation 25

Contact Us 26

Disclaimer 26





List of Tables

Number of Products Under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2012 6

Products under Development for Uterine Leiomyoma (Uterine Fibroids) — Comparative Analysis, H1 2012 7

Number of Products under Development by Companies, H1 2012 8

Number of Products under Investigation by Universities/Institutes, H1 2012 9

Comparative Analysis by Late Stage Development, H1 2012 10

Comparative Analysis by Mid Clinical Stage Development, H1 2012 11

Products under Development by Companies, H1 2012 12

Products under Investigation by Universities/Institutes, H1 2012 13

Abbott Laboratories, H1 2012 14

Assessment by Monotherapy Products, H1 2012 15

Assessment by Stage and Route of Administration, H1 2012 17

Assessment by Stage and Molecule Type, H1 2012 19

Uterine Leiomyoma (Uterine Fibroids) Therapeutics — Drug Profile Updates 22





List of Figures

Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H1 2012 6

Products under Development for Uterine Leiomyoma (Uterine Fibroids) — Comparative Analysis, H1 2012 7

Products under Development by Companies, H1 2012 8

Products under Investigation by Universities/Institutes, H1 2012 9

Late Stage Products, H1 2012 10

Mid Clinical Stage Products, H1 2012 11

Assessment by Monotherapy Products, H1 2012 15

Assessment by Route of Administration, H1 2012 16

Assessment by Stage and Route of Administration, H1 2012 17

Assessment by Molecule Type, H1 2012 18

Assessment by Stage and Molecule Type, H1 2012 19

• Female Hypoactive Sexual Desire Disorder – Pipeline Review, H1 2013
• Cervical Dysplasia – Pipeline Review, H1 2013
• EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
• Female Sexual Dysfunction – Pipeline Review, H1 2013
• Menopausal Disorders – Pipeline Review, H1 2013
• Menopausal Hot Flashes – Pipeline Review, H1 2013
• Uterine Fibroids – Pipeline Review, H1 2013
• Vaginal Atrophy (Atrophic Vaginitis) – Pipeline Review, H1 2013
• Contraceptives – Pipeline Review, H1 2013
• Dysmenorrhea – Pipeline Review, H1 2013
• Endometriosis – Pipeline Review, H1 2013
• Women Infertility – Pipeline Review, H1 2013
• Premature Labor (Tocolysis) – Pipeline Review, H2 2012
• Vasomotor Symptoms of Menopause – Pipeline Review, H2 2012
• Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
• Premature Ovarian Failure – Pipeline Review, H2 2012
• Premenstrual Syndrome – Pipeline Review, H2 2012
• Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy
• Endometriosis Global Clinical Trials Review, H2, 2012
• Primary Dysmenorrhea – Pipeline Review, H2 2012